Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2940MR)

This product GTTS-WQ2940MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2940MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7006MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ3998MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ9575MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ6369MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ12594MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ14650MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ13128MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12490MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW